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Abstract
Background: Endothelial dysfunction is an important precursor to the development of atherosclerosis, and has
been suggested to play a role in the increased cardiovascular risk in patients with end stage renal disease.
Endothelial function improves rapidly following post kidney transplantation, but the long term change remains
unclear. Hypothesizing that endothelial function would remain improved long term post kidney transplantation, we
evaluated the longitudinal change of endothelial function, measured by flow-mediated dilation (FMD) of the
brachial artery, from months 1 to 24 post transplantation. Given the previously reported association of fibroblast
growth factor 23 (FGF-23) with endothelial dysfunction, we also examined changes in the association between FGF-23
levels and the change in FMD following kidney transplantation.
Methods: We performed a prospective cohort study of 149 kidney transplant recipients, measuring endothelial
function by FMD at months 1, 12, and 24 post-transplant. FGF-23 levels were measured at months 1 and 24
post-transplant. Linear mixed effects models were used to assess both the unadjusted and adjusted outcomes.
Results: The cohort (mean age 49 ± 13 years) was 74 % male and 75 % white. The median FMD was 6.3 %
(IQR: 3.4, 10.2), 5.4 % (IQR: 3.1, 8.5), and 5.6 % (IQR: 3.5, 9.1) at 1, 12, and 24 months, respectively. After
adjustment for covariates, compared to month 1, no change occurred in FMD at 12 months (−0.66 %; 95 % CI: −1.
81 %, 0.49 %; P = 0.262) or 24 months (−0.25 %; 95%CI: −1.76 %, 1.26 %; P = 0.746). FGF-23 decreased significantly over
time (P = 0.024), but there was no significant association between FGF-23 and FMD (P = 0.799).
Conclusion: Endothelial function remained stable at 12 and 24 months from 1 month post-kidney transplant,
indicating that the improved endothelial function seen with transplant is maintained up to 2 years post
transplantation. There was also no significant association between FGF-23 and endothelial function following kidney
transplantation.
Keywords: Cardiovascular disease, Cardiovascular risk factors, Endothelial dysfunction, Flow-mediated dilation, Kidney
transplantation
Background
Patients with end stage renal disease (ESRD) requiring
maintenance dialysis experience a high incidence and
prevalence of cardiovascular disease, which is conse-
quently a leading cause of mortality in this patient popu-
lation [1]. Successful kidney transplantation is associated
with lower cardiovascular morbidity and mortality com-
pared to patients who remain on the transplant wait list
[2–4]. Despite improvement in traditional cardiovascular
risk factors following kidney transplantation, the death
rate from cardiovascular disease in patients with a func-
tioning graft remains high compared to the general
population [5]. Understanding the progression of unique
cardiovascular risk factors associated with kidney trans-
plantation may provide potential opportunities for risk
modification leading to improved survival.
One marker of increased cardiovascular risk is impair-
ment of endothelial function, which is an important
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precursor to the development of atherosclerosis.
Impaired brachial artery endothelial function serves as a
marker of underlying atherosclerotic risk and is a reli-
able surrogate for coronary endothelial function [6]. Sev-
eral previous studies have reported impaired endothelial
function in patients with chronic kidney disease [7–10].
Endothelial dysfunction is universally present in dialysis
patients, and it can predict cardiovascular events in pa-
tients with kidney disease [7, 8, 11, 12]. Several studies
have shown that endothelial function improves immediately
post-transplant compared to pre-transplant [10, 13, 14].
However, no long term study of repeated endothelial func-
tion assessment has been performed in medical stable
kidney transplant recipients.
A high concentration of circulating Fibroblast Growth
Factor 23 (FGF-23) is also an independent risk factor for
kidney disease progression, cardiovascular disease and mor-
tality [15–21]. Fibroblast Growth Factor 23 is linked to
endothelial dysfunction in patients with ESRD [19, 22–24]
and FGF-23 levels have been shown to significantly de-
crease following successful kidney transplantation [15].
However, the degree to which endothelial function changes
in conjunction with decreasing levels of FGF-23 following
kidney transplant remains unclear.
Our aim was to evaluate endothelial dysfunction longi-
tudinally, as measured by flow-mediated dilation (FMD),
in a cohort of medically stable, kidney transplant recipi-
ents starting at 1 month post transplantation. In
addition, we evaluated FGF-23 concentration following
transplant to investigate a possible association between
FGF-23 levels and changes in endothelial function. We
hypothesized that long-term endothelial function would
remain improved following successful kidney transplant-
ation, and the longitudinal reduction in FGF-23 levels in
the setting of a functioning allograft would be associated
with improved endothelial function.
Methods
Study design
We conducted a single-center, prospective cohort study.
De novo kidney transplant recipients were recruited
from the Vanderbilt University Medical Center (VUMC)
Renal Transplant Clinic from August 2009 through May
2013. Inclusion criteria included patients aged ≥ 18 years
who were undergoing or had recently undergone kidney
transplantation. There were no exclusion criteria. Con-
sent for participation in the study was obtained prior to
discharge from the hospital following kidney transplant.
Given the widely dispersed geographic area of patients
on the kidney transplant waiting list at VUMC, obtain-
ing a baseline FMD measurement prior to kidney trans-
plantation was not logistically practical, thus patients
were first evaluated at 1 month following kidney trans-
plantation. Additional follow up visits were performed at
12 and 24 months. All patients gave informed consent
and the VUMC Institutional Review Board approved the
study protocol.
Flow-mediated dilation protocol
A single, licensed sonographer blinded to clinical details
and previous FMD measurements of the study partici-
pants obtained the ultrasound images and performed the
FMD study. The initial FMD was measured at 1 month
following transplant. Follow up FMD examinations were
performed at 12 and 24 months.
Flow-mediated dilation was performed as originally
described by Celermajer and colleagues [25]. Endothelial
function of the brachial artery was measured following
ischemic reactive hyperemia to determine the resulting
FMD. Each patient in the cohort was requested not to
eat, drink (including alcohol, caffeine, etc.), or smoke for
12 h prior to the examination. The criteria to begin the
study required a patient’s systolic blood pressure to be
stable within 5 mmHg over several, separate recordings
performed at two-minute intervals. A longitudinal image
of the brachial artery was taken in the supine position at
rest with a high-resolution ultrasound to obtain the
baseline diameter (10.0 MHz linear array transducer,
Philips iU 22, Andover, MA). A pneumatic tourniquet
was inflated around the lower arm distal to the site at
which the baseline brachial artery diameter was mea-
sured. The tourniquet was inflated to 250 mmHg for a
total time of 5 min. Reactive hyperemia was measured
after restoration of blood flow following the release of
the pneumatic blood pressure cuff. Brachial artery diam-
eter was measured at 60 s and 90 s following the release
of the blood pressure cuff. Arterial diameter was mea-
sured from the media-adventitia interface.
The FMD studies were evaluated by one reviewer (CK)
for consistency and accuracy of the brachial artery diam-
eter measurements at the 60 and 90 s time points fol-
lowing the induction of hyperemia after the deflation of
the pneumatic tourniquet.
Flow-mediated dilation calculation
Endothelium-dependent FMD was expressed as the per-
centage change of the brachial artery diameter from
baseline to the diameter following reactive hyperemia
(Post-test diameter-Baseline diameter)/Baseline diam-
eter). The larger percent change of the two time points
measured (60 or 90 s) served as the reported FMD. An
increase in FMD over time indicates improved endo-
thelial function. An acceptable reproducibility during
longitudinal evaluations is a mean difference of less
than 2–3 % [26]. Therefore, we defined an improvement
in FMD of more than 3 % as necessary to detect a treat-
ment benefit following kidney transplantation [27]. We
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also defined normal endothelial function as a FMD greater
than 6.3 % [28].
Fibroblast growth factor-23 measurement
Serum concentrations of FGF-23 were measured in du-
plicate after a single thaw of stored blood specimens
using an intact FGF-23 ELISA kit (Immutopics, San
Clemente, CA). Measurements in blood samples ob-
tained at 1 month following kidney transplant served as
the initial FGF-23 level. The longitudinal assessment of
FGF-23 levels was performed on blood samples obtained
at the 24-month follow-up. The coefficient of determin-
ation from the primary standard deviation curve for the
FGF-23 measurements was 0.9999, indicating high
reproducibility.
Outcomes
The primary outcome was defined as the change in
FMD from the one-month post kidney transplant
evaluation to the 12-month follow-up. Secondary out-
comes include the change in FMD from 1 month to
24 months following kidney transplant, change in
FMD from 12 months to 24 months following kidney
transplant, and change in FGF-23 from 1 month to
24 months post-kidney transplant. We also examined
the association between FGF-23 levels and the pro-
gression of FMD from 1 month to 24 months follow-
ing kidney transplantation.
Statistical analysis
Descriptive statistics were presented as median with
interquartile range (IQR) or mean with standard devi-
ation (SD) for continuous variable and as percentages
for categorical variables. We compared the differences in
patients characteristics at month one between the pa-
tients who followed up at 12 months post transplant
with those patients who did not return for evaluation
using either Pearson’s chi-square test (for categorical
variables) or Wilcoxon rank sum test (for continuous
variables). A linear mixed effects model with random in-
tercepts was used to assess the change in FMD over
time without and with adjustment for age, race, gender,
smoking history (pack years), months on dialysis prior to
transplant, cardiovascular disease, mean arterial pressure
(MAP), diabetes, and estimated glomerular filtration rate
(eGFR). Months on dialysis prior to transplant, eGFR,
MAP, pack years, and age were included in the models
as non-linear terms using restricted cubic splines. Car-
diovascular disease was defined as a history of coronary
artery disease, myocardial ischemia, reperfusion (coron-
ary artery bypass or percutaneous stent), congestive
heart failure, arrhythmia, stroke, or peripheral vascular
disease.
A linear mixed effects model with random intercepts
was used to examine the change in FGF-23 concentra-
tions over time without and with adjustment for age,
race, gender, cardiovascular disease, time on dialysis
prior to transplant, and eGFR. In order to meet the nor-
mality assumption of the residuals, FGF-23 concentra-
tions were natural logarithmic transformed. All the
covariates for both models were chosen a priori. Ana-
lyses were performed using R, version 3.1.2 (http://
www.r-project.org/). The 5 % significance level (2 sided)
was used.
Results
Patient demographic and other characteristics
The study cohort included 149 patients who underwent
evaluation at 1 month following kidney transplantation.
Demographic and other patient characteristics are pre-
sented in Table 1. The cohort (n = 149, mean age 49, SD
= 39 years) was 74 % male and 75 % White. The most
common underlying etiology for ESRD was vascular dis-
ease (52 %; defined as ESRD due to diabetes- and/or
hypertension-induced renal failure). Seventy-two pa-
tients (48 %) reported to be either current or former
smokers, and 40 and 38 % of the cohort had a history of
cardiovascular disease and diabetes, respectively. The
median time on dialysis prior to kidney transplant for
the cohort was 20.3 months (IQR: 6.9, 47.2). Fifteen per-
cent of the study cohort did not require hemodialysis
prior to transplant. In regards to medications that may
affect the progression of endothelial function, only 3 %
(4/149) of the cohort were taking angiotensin converting
enzymes inhibitors and angiotensin receptor blockers,
4 % (6/149) were taking a vasodilator, 7 % (11/149) were
taking an alpha blocker, and 20 % (29/149) were taking a
statin. Throughout the two-year study period, there was
one major cardiac event (myocardial infarction) that oc-
curred between the 12 and 24-month follow up. There
were six reported events of angina (three in the peri-
operative period prior to the 1 month evaluation, two
events prior to the 12 month follow up, one event prior
to the 24 month follow up) and one dysrhythmic event
(occurred prior to the 12 month follow up).
Eighty-six patients had subsequent clinical follow-up
at 12 months, and 44 patients at 24 months (Fig. 1). An
analysis comparing characteristics of the patients who
did and did not remain in the study through the 12-
month evaluation showed no statistically significant dif-
ferences (For details, see Table 1 of the Supplemental
Appendix). The two most common reasons (Fig. 1) for
discontinuation prior to the 12-month visit were missing
both the clinic appointment and ultrasound evaluation
(18/63, 29 %) or missing only the ultrasound evaluation
(18/63, 29 %).
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Primary outcome
The median FMD at one-month post-kidney trans-
plant for the cohort was 6.3 % (IQR: 3.4–10.2) and at
12 months was 5.4 % (IQR: 3.1–8.5) (Table 2). Based
on our definition of a normal FMD (>6.3 %), 52 %
(77/149) of the population had normal endothelial
function at 1 month and 49 % (42/86) at 12 months.
In the unadjusted model, FMD remained stable over
time (overall P = 0.622). Compared to month one,
FMD numerically decreased by 0.56 % (95 % CI:
−1.70, 0.57, P = 0.332) at month 12. In the adjusted
model controlling for age, race, gender, smoking
history (pack years), months on dialysis prior to
transplant, cardiovascular disease, MAP, diabetes and
eGFR, FMD remained stable over time (overall
P = 0.532). Compared to month one in the adjusted
Table 1 Characteristics of the kidney transplant cohort at
one-month post-transplantation
Characteristic N = 149
Age at transplant (years) 49 (40, 59)
Race
White 112 (75 %)
Black 34 (23 %)
Other 3 (2 %)
Sex (male) 111 (74 %)
BMI 27.3 (23.5, 30.5)
Tobacco use
Never 77 (52 %)
Current 14 (9 %)
Former 58 (39 %)
Pack Years 11.5 (3, 24.0)
Cardiovascular diseasea 59 (40 %)
Diabetes 56 (38 %)
Hypertension 142 (95 %)
Hyperlipidemia 83 (56 %)
Months on Dialysis pre-transplant 20.3 (6.9, 47.2)
Primary cause of end-stage renal disease
Vascular Disease 78 (52 %)
Glomerular Disease 31 (21 %)
Tubulointerstitial Disease 9 (6 %)
Cystic Disease 19 (13 %)
Structure Disease 1 (1 %)
Renal Neoplasia 1 (1 %)
Other 10 (7 %)
Estimated Glomerular Filtration Rate (ml/min/m2) 58 (48, 69)
Mean Arterial Pressure (mm Hg) 95.7 (87.3, 103.7)
Induction Immunosuppression
Alemtuzumab 134 (90 %)
Basiliximab 14 (9 %)
Anti-Thymocyte Globulin 1 (1 %)
Maintenance Immunosuppression
Tacrolimus 146 (98 %)
Mycophenolate 143 (96 %)
Prednisone 81 (54 %)
Anti-Hypertensive Medication
Alpha Blockers 11 (7 %)
Beta Blockers 88 (59 %)
Calcium Channel Blockers 77 (52 %)
ACEb Inhibitors 4 (3 %)
Angiotensin Receptor Blocker 4 (3 %)
Vasodilators 6 (4 %)
Table 1 Characteristics of the kidney transplant cohort at
one-month post-transplantation (Continued)
Statin Therapy 29 (20 %)
Slow Graft Function 23 (16 %)
Delayed Graft Function 8 (5 %)
Values expressed as median (25th, 75th percentiles) or number (percent)
aCardiovascular disease includes coronary artery disease, myocardial infarction,
coronary artery bypass grafting, percutaneous coronary intervention,
congestive heart failure, arrhythmia, stroke, and peripheral vascular disease
bAngiotensin Converting Enzyme
Fig. 1 Flowchart describing the follow-up details of the study cohort
of kidney transplant patients. (Abbreviations: LTFU: Lost to follow-up;
CRC: Clinical research center (location of flow mediated dilation
evaluation); HD: hemodialysis)
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model, FMD numerically decreased by 0.66 % at
month 12, but this was not statistically significant
(95 % CI: −1.81, −0.49, P = 0.262) (Table 3). Females
had significantly increased FMD compared to males
(P = 0.031), and FMD decreased significantly with age
(P = 0.038).
Secondary outcomes
FMD at 24 months
The median FMD for the cohort at 24 months was 5.6 %
(IQR: 3.5–9.1) (Fig. 2). Based on our definition of a nor-
mal FMD (>6.3 %), 50 % (22/44) of the population had
normal endothelial function at 24 months. In the ad-
justed model, FMD remained stable from 1 month to
24 months (−0.25 %, 95 % CI: −1.76, 1.26, P = 0.746) and
from 12 months to 24 months (0.41 %, 95 % CI: −1.19,
2.01, P = 0.614) post-transplantation.
FGF-23 levels
Forty-five patients were included in the analysis that
measured FGF-23 at 1 month and 24 months follow-up
after kidney transplantation. Fibroblast Growth Factor
23 decreased significantly over time (P = 0.02) (Fig. 3).
At month 24, FGF-23 decreased 36 % (95 % CI: 7 %,
56 %, P = 0.024) compared to month one.
Flow-mediated dilation and FGF-23 level
Adjusting for age, race, gender, cardiovascular disease,
time on dialysis prior to transplant and eGFR, there was
no statistically significant relationship between FGF-23
and FMD following kidney transplant (P = 0.799). With
one interquartile range (~100 picograms per milliliters)
decrease in FGF-23, FMD decreased by 0.11 % (95 % CI:
−0.93, 0.71, P = 0.799) over time from 1 month to
24 months post transplant. In addition, there was no sig-
nificant association between FGF-23 and FMD at month
one (P = 0.959) or month 24 (P = 0.699).
Discussion
Endothelial dysfunction is characterized by an impaired
vasodilation in response to changes in the local
hemodynamic forces and vasoactive substances and can
initiate the atherosclerotic pathway [29]. Since athero-
sclerotic disease initiated by endothelial dysfunction is a
frequent cause of cardiovascular morbidity and mortality
in patients with ESRD, studying changes in endothelial
function by FMD may provide important information to
evaluate potential interventions to address risk modifica-
tion for cardiovascular disease following kidney trans-
plantation [29]. Therefore, the aim of this study was to
evaluate the long term evolution of endothelial function
in kidney transplantation. We report that the improved
endothelial function observed immediately post trans-
plant is well maintained up to 2 years post transplant-
ation. In multivariate models, only age and sex were
predictors of FMD.
Endothelial dysfunction is universally present in dialy-
sis patients, and previous studies have demonstrated a
favorable change in FMD comparing pre and post-
transplantation. Kocak et al demonstrated that FMD sig-
nificantly improved 14 days after kidney transplant
Table 2 Changes in flow mediated dilation and other clinical
characteristics during the study period
Parameters
Flow Mediated Dilatation (percentage)
Month 1 6.3 (3.4, 10.2)
Month 12 5.4 (3.1, 8.5)
Month 24 5.6 (3.5, 9.1)
Body Mass Index (kg/m2)
Month 1 27.3 (23.5, 30.5)
Month 12 29.2 (26.2, 34.0)
Month 24 31.0 (26.2, 33.4)
Estimated Glomerular Filtration Rate (ml/min/1.73*m2)
Month 1 58 (48, 69)
Month 12 59 (47, 71)
Month 24 57 (45, 69)
Mean Arterial Pressure (mmHg)
Month 1 95.7 (87.3, 103.7)
Month 12 96.3 (90.8, 103.7)
Month 24 98.7 (92.5, 104.7)
Values expressed as median (25th, 75th percentiles)
Table 3 Multivariable linear regression model of flow mediated
dilation in kidney transplant recipients
Covariate Effect S.E. 95 % CIa P
Predictors of FMD
Age at transplant −0.06 0.58 −1.20, 1.08 0.038
Race (reference: white) −0.94 0.87 −2.63, 0.76 0.382
Sex (reference: males) 1.71 0.79 0.15, 3.26 0.031
Diabetes −1.27 0.75 −2.74, 0.20 0.091
Cardiovascular Diseaseb −0.87 0.76 −2.35, 0.62 0.252
Pack Years −0.44 0.47 −1.36, 0.48 0.150
Glomerular filtration rate −0.47 0.43 −1.32, 0.37 0.362
Mean arterial pressure −0.42 0.39 −1.19, 0.34 0.976
Time on dialysis −0.45 0.8 −2.01, 1.1 0.984
FMD 1 month – > 12 months −0.66 0.59 −1.81. 0.49 0.262
FMD 1 month – > 24 months −0.25 0.77 −1.76, 1.26 0.746
FMD 12 months – > 24 months 0.41 0.81 −1.19, 2.01 0.614
a95% Confidence Interval: Lower bound, Upper bound
bCardiovascular disease includes coronary artery disease, myocardial infarction,
coronary artery bypass grafting, percutaneous coronary intervention,
congestive heart failure, arrhythmia, stroke, and peripheral vascular disease
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(6.69 % vs. 10.50 %, P < 0.001) [14]. In that study, 30
chronic hemodialysis patients with an average age of
38 years were included following living donation kidney
transplant [14]. Oflaz et al evaluated endothelial function
in 22 ESRD patients with an average age of 34 years and
body mass index (BMI) of 23.1 kilograms/meter2 (kg/
m2) [13], and reported a significant improvement in
FMD from pre-transplant (6 ± 3.7 %) versus 6 months
(8.3 ± 2.3 % (P = <0.001)) and 12 months following trans-
plant (12 months: 12.1 ± 3.6 % (P = <0.001)) [13]. Yilmaz
et al showed that endothelium-dependent vasodilation
improved within 6 months following kidney transplant
in 161 patients with an average age of 31 and average
BMI of 25.3 kg/m2 [10]. Flow mediated dilation prior to
transplant was 5.2 ± 0.8 and 6 months following trans-
plant was 6.6 ± 0.7 (P = <0.001) [10].
Our study, in contrast, examines the longer-term effect
of kidney transplantation on endothelial function, show-
ing that FMD remains relatively stable from 1 month to
24 months post transplant. The patients in our cohort
were initially evaluated at 1 month post transplant, a
time when many of the biochemical abnormalities
related to uremia have corrected and complications re-
lated to rejection or infection are rare.
Strengths of our study include the size of our cohort
and duration of longitudinal follow-up. Moreover, the
population in our study is older and includes a substantial
proportion of patients with cardiovascular disease or dia-
betes, compared to the previously mentioned studies that
were conducted among select groups of relatively young
transplant recipients. Thus, a potential explanation for the
lack of ongoing improvement in FMD in our study is the
high cardiovascular risk profile of the transplant recipi-
ents. However, our study population is more reflective of
the ESRD and transplant recipient population in the
United States and Europe, which improves the
generalizability of our findings compared to prior reports.
Another strength of our study was that a single sonogra-
pher performed the FMD study in the entire cohort,
which improves the reliability of the results. The advan-
tage of using brachial artery FMD as a surrogate for
coronary artery endothelial health is that the test is non-
invasive with reproducible results in the same patient over
time when performed by the same examiner.
Fig. 2 Box plot of the flow-mediated dilation measured longitudinally in the cohort population following kidney transplantation
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A limitation of the study is the lack of a pre-transplant
FMD measurement. There are reports that note FMD
improves rapidly with favorable modification of cardio-
vascular risk factors. In the prospective, randomized
RECIFE trial, FMD was shown to significantly improve
in just 6 weeks (4.93+/−0.81 % to 7.0+/−0.79 % (P =
0.02)) in a high cardiovascular risk patient population
(i.e. acute myocardial infarction or unstable angina) with
hyperlipidemia who took pravastatin compared to pla-
cebo [30]. This study suggests that endothelial function
rapidly improves with interventions that favorably mod-
ify cardiovascular risk, such as kidney transplantation.
When compared to our study, the report by Yilmaz et al.
[1] provides further insight into the potential improve-
ment in FMD during the early post-operative period.
The average FMD at 1 month after transplant in our
study was 6.4 % which is similar to the FMD at 6 months
following transplant (6.6 %) in the Yilmaz et al report;
however, this measurement corresponded to a 27 % in-
crease in FMD when compared to the pre-transplant
FMD of 5.2 %. Without a pre-transplant FMD measure-
ment, the immediate changes in endothelial function
within the early post-operative period were not captured in
our study design compared the prior reports [10, 13, 14]
where the baseline FMD measurement was based on pre-
transplant evaluations. However, we feel our study does
provide additional information on the long-term effect of
kidney transplantation on endothelial function. It is inter-
esting to note endothelial function as measured by FMD re-
mains stable during the first 2 years post transplantation
despite the ongoing adverse metabolic effects from trans-
plant immunosuppression and possible decline in kidney
function.
Fibroblast Growth Factor-23 has been shown to be sig-
nificantly elevated in patients with chronic kidney dis-
ease as FGF-23 metabolism and clearance are modified
[31, 32], which subsequently improves following kidney
transplantation [15]. Several studies have shown a link
between elevated FGF-23 levels and increased cardiovas-
cular risk. In a prospective study of 984 kidney trans-
plant patients, Wolf et al showed that elevated FGF-23
levels post-operatively were independently associated
with increased mortality and allograft loss [15]. Elevated
FGF-23 levels have been correlated with impaired
Fig. 3 Box plot of the fibroblast growth factor 23 levels measured longitudinally in the cohort population following kidney transplantation
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endothelial function in patients [19, 22–24]. Mirza et al
demonstrated an association between higher FGF-23
levels and impaired vasoreactivity, as well as, a correl-
ation between arterial stiffness with patients with renal
dysfunction and higher FGF-23 levels [24]. Yilmaz et al
reported an independent correlation of high FGF-23 and
impaired FMD in patients with stage III and IV renal
failure (20). The relationship between decreased FGF-23
concentrations and endothelial function following kidney
transplantation is not well studied, but one report
showed in 161 patients that endothelium-dependent
vasodilation improved in the 6 months following kidney
transplant, which corresponded to a significant decrease
in FGF-23 levels [10]. In our study, there was no signifi-
cant association between FGF-23 levels and FMD over
24 months following kidney transplant despite a signifi-
cant reduction in FGF-23 concentration over the two-
year period. The difference in outcomes between the
two studies could be a result of the shorter follow up
time in the Yilmaz et al report (6 months versus
24 months, respectively) and, as previously stated, the
dissimilarity in the demographic profiles.
Further limitations of our study include the high per-
centage of patients who did not complete the follow up.
A sensitivity analysis did not show any significant demo-
graphic or clinical differences between patients who did
not return for the 12 month follow up compared to pa-
tients who completed the study, suggesting that any bias
is likely to be minimal, though in characteristics not ex-
amined cannot be ruled out. Another limitation of our
study is that measurements for maximal FMD were ob-
tained at set time points of 60 and 90 s. Without a con-
tinuous evaluation, the maximum diameter change
secondary to reactive hyperemia may not have been cap-
tured with these set time point measurements. In
addition, FMD can be affected by temperature, foods,
drugs, sympathetic stimuli, environmental factors, and
patient’s positions, which can vary over time at each
evaluation. The study protocol attempted to minimize
this variation by asking all patients to not consume to-
bacco, food or liquids for 8 h prior to the evaluation. In
addition, cardiovascular medication such as angiotensin
converting enzyme inhibitors and statins that could
affect endothelial function were not controlled for in the
study cohort.
Conclusions
In a single center, prospective study of medically stable,
kidney transplant recipients who were initially evaluated
at 1 month following surgery, FMD remained stable over
a 24 month follow up period. Consistent with previous
work, FGF-23 levels significantly decreased following
kidney transplant, however this decrease was not associ-
ated with improvement in FMD. The stable FMD in our
study cohort suggests that the improvement in endothe-
lial function is maintained up to 2 years post transplant-
ation. However, the lack of continued improvement in
endothelial function may contribute to the persistently
elevated cardiovascular risk in transplant patients com-
pared to the general population despite improved renal
function. Further prospective research regarding endo-
thelial function following kidney transplant would pro-
vide important insight into possible mechanisms
whereby transplantation impacts cardiovascular health,
which would allow interventions aimed at the preven-
tion and reversibility of cardiovascular diseases.
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